Biometric Imaging Announces Posting of New Web Site: www.biometric.com.

MOUNTAIN VIEW, Calif.--(BW HealthWire)--Oct. 7, 1998--Biometric Imaging announced today the posting of their new web site -- http://www.biometric.com.

The web site includes a Home page, Corporate Profile, Technology section, Products section, What's New section, and Contact Us information. Within the Technology Section, the Company features their proprietary technology, microvolume fluorimetry and their novel drug therapy monitoring approach called pharmacocytometrics. Within the Products section, the Company describes how their proprietary technology is used for six application areas: high throughput screening for drug discovery, drug therapy monitoring, AIDS Management, Transfusion Medicine, Cancer, and Specialty Hematology.

The What's New section features the Company's latest FDA 510(k) clearances for three of their products: the CEQer(R) Assays for enumerating leukocytes in platelet rich plasma and red blood cell products and STELLer(R) CD34 Assay for enumerating CD34+ stem cells in whole blood.

The web site will be updated monthly and will feature the latest information concerning Biometric Imaging. These include new product releases, recent FDA 510(k) product clearances, attendance at upcoming exhibits and conferences, special events, and investor information.

Biometric Imaging is a biomedical company that develops, manufactures and markets instruments and assays that count cells and monitor cell function. The Company's goal is to offer cost-effective cell analysis applications to clinics, hospitals, blood banks and cancer management centers for disease management and therapy monitoring. Biometric Imaging has also developed a high throughput screening platform that is being marketed by Perkin-Elmer Corp. (NYSE: PKN). In addition, the Company collaborates with pharmaceutical companies to apply cell analysis techniques to improve the patient selection for clinical trials.